Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study

U. Jaakkola, J. Kallio, R.J. Heine, M.G.A.A.M. Nijpels, L.M. Hart, J.A. Maassen, L.M. Bouter, C.D.A. Stehouwer, J.M. Dekker

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81-4.81, P<0.001) and the Leu7Pro polymorphism-obesity interaction, with a remarkable 12-fold risk (OR 12.33; 95% CI 1.18-128.35, P<0.05). The Leu7Pro polymorphism modified significantly the 10-year incidence of cardiovascular events, causing a 7.6-fold increase in the hazard ratio (HR 7.58; 95% CI 2.87-20.03, P<0.001) in the obese but not in the nonobese subjects. The results indicate that obesity may be a pivotal factor in multiplying the disease risk associated with the Leu7Pro polymorphism in preproNPY
Original languageEnglish
Pages (from-to)150-152
Number of pages3
JournalEuropean Journal of Clinical Nutrition
Volume63
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Neuropeptide Y
Cardiovascular Diseases
Obesity
Odds Ratio
Confidence Intervals
Type 2 Diabetes Mellitus
Atherosclerosis
Glucose
Incidence
preproneuropeptide Y

Bibliographical note

DA - 20090107 LA - eng JT - European journal of clinical nutrition

Cite this

Jaakkola, U., Kallio, J., Heine, R. J., Nijpels, M. G. A. A. M., Hart, L. M., Maassen, J. A., ... Dekker, J. M. (2009). Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study. European Journal of Clinical Nutrition, 63(1), 150-152. https://doi.org/10.1038/sj.ejcn.1602964
Jaakkola, U. ; Kallio, J. ; Heine, R.J. ; Nijpels, M.G.A.A.M. ; Hart, L.M. ; Maassen, J.A. ; Bouter, L.M. ; Stehouwer, C.D.A. ; Dekker, J.M. / Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study. In: European Journal of Clinical Nutrition. 2009 ; Vol. 63, No. 1. pp. 150-152.
@article{4c56e900bc544463ab50d5c86f192a56,
title = "Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study",
abstract = "The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95{\%} confidence interval (CI) 1.81-4.81, P<0.001) and the Leu7Pro polymorphism-obesity interaction, with a remarkable 12-fold risk (OR 12.33; 95{\%} CI 1.18-128.35, P<0.05). The Leu7Pro polymorphism modified significantly the 10-year incidence of cardiovascular events, causing a 7.6-fold increase in the hazard ratio (HR 7.58; 95{\%} CI 2.87-20.03, P<0.001) in the obese but not in the nonobese subjects. The results indicate that obesity may be a pivotal factor in multiplying the disease risk associated with the Leu7Pro polymorphism in preproNPY",
author = "U. Jaakkola and J. Kallio and R.J. Heine and M.G.A.A.M. Nijpels and L.M. Hart and J.A. Maassen and L.M. Bouter and C.D.A. Stehouwer and J.M. Dekker",
note = "DA - 20090107 LA - eng JT - European journal of clinical nutrition",
year = "2009",
doi = "10.1038/sj.ejcn.1602964",
language = "English",
volume = "63",
pages = "150--152",
journal = "European Journal of Clinical Nutrition",
issn = "0954-3007",
publisher = "Nature Publishing Group",
number = "1",

}

Jaakkola, U, Kallio, J, Heine, RJ, Nijpels, MGAAM, Hart, LM, Maassen, JA, Bouter, LM, Stehouwer, CDA & Dekker, JM 2009, 'Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study' European Journal of Clinical Nutrition, vol. 63, no. 1, pp. 150-152. https://doi.org/10.1038/sj.ejcn.1602964

Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study. / Jaakkola, U.; Kallio, J.; Heine, R.J.; Nijpels, M.G.A.A.M.; Hart, L.M.; Maassen, J.A.; Bouter, L.M.; Stehouwer, C.D.A.; Dekker, J.M.

In: European Journal of Clinical Nutrition, Vol. 63, No. 1, 2009, p. 150-152.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study

AU - Jaakkola, U.

AU - Kallio, J.

AU - Heine, R.J.

AU - Nijpels, M.G.A.A.M.

AU - Hart, L.M.

AU - Maassen, J.A.

AU - Bouter, L.M.

AU - Stehouwer, C.D.A.

AU - Dekker, J.M.

N1 - DA - 20090107 LA - eng JT - European journal of clinical nutrition

PY - 2009

Y1 - 2009

N2 - The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81-4.81, P<0.001) and the Leu7Pro polymorphism-obesity interaction, with a remarkable 12-fold risk (OR 12.33; 95% CI 1.18-128.35, P<0.05). The Leu7Pro polymorphism modified significantly the 10-year incidence of cardiovascular events, causing a 7.6-fold increase in the hazard ratio (HR 7.58; 95% CI 2.87-20.03, P<0.001) in the obese but not in the nonobese subjects. The results indicate that obesity may be a pivotal factor in multiplying the disease risk associated with the Leu7Pro polymorphism in preproNPY

AB - The leucine7 to proline7 (Leu7Pro) polymorphism in preproneuropeptide Y (preproNPY) has been associated with accelerated atherosclerosis and type II diabetes, both of which are obesity-related diseases. The current study evaluated the impact of obesity on the disease risk linked to the Leu7Pro polymorphism of preproNPY in 393 elderly subjects. In 6 years follow-up, the polymorphism alone did not change the risk for abnormal glucose regulation, while obesity was associated with a significant 3-fold risk (odds ratio (OR) 2.95; 95% confidence interval (CI) 1.81-4.81, P<0.001) and the Leu7Pro polymorphism-obesity interaction, with a remarkable 12-fold risk (OR 12.33; 95% CI 1.18-128.35, P<0.05). The Leu7Pro polymorphism modified significantly the 10-year incidence of cardiovascular events, causing a 7.6-fold increase in the hazard ratio (HR 7.58; 95% CI 2.87-20.03, P<0.001) in the obese but not in the nonobese subjects. The results indicate that obesity may be a pivotal factor in multiplying the disease risk associated with the Leu7Pro polymorphism in preproNPY

U2 - 10.1038/sj.ejcn.1602964

DO - 10.1038/sj.ejcn.1602964

M3 - Article

VL - 63

SP - 150

EP - 152

JO - European Journal of Clinical Nutrition

JF - European Journal of Clinical Nutrition

SN - 0954-3007

IS - 1

ER -